Forest Laboratories Announces Positive Phase III Data for Alzheimer's Drug
Posted on: Friday, 1 August 2008, 06:00 CDT
Forest Laboratories has presented positive Phase III data of a once-daily extended-release formulation of Namenda for Alzheimer's disease.
The study evaluated the efficacy, safety and tolerability of an innovative, proprietary, 28mg once-daily extended-release formulation of Namenda (memantine HCl) compared to placebo in outpatients with moderate to severe Alzheimer's disease already being treated with a cholinesterase inhibitor (donepezil, galantamine or rivastigmine).
In the study, patients treated with once-daily extended-release Namenda experienced significant improvements in cognitive performance and global clinical status compared to those receiving placebo. Patients treated with once-daily extended-release Namenda also experienced significant improvements in verbal fluency and behavioral symptoms as compared to placebo. The study also demonstrated that once-daily extended-release memantine was well tolerated.
Marco Taglietti, executive vice president and chief medical officer at Forest, said: "With this novel formulation, the efficacy and tolerability of Namenda is delivered in a more convenient, once-daily dose."
Source: Datamonitor
Related Articles
- New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
- New Data Highlight Positive Results of Namenda(R) (Memantine HCl) Once-Daily Extended-Release Formulation
- FDA Approves Once-Daily Veramyst(TM) (Fluticasone Furoate) Nasal Spray for Treatment of Seasonal and Year-Round Allergy Symptoms in Adults and Children As Young As Two Years
- Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
- HIV/AIDS Patients Get 1st Once-Daily Pill
- Patient Satisfaction With Once-Daily Dosing Of HIV Fixed-Dose Combination Tablet EPZICOM
- Clinical Studies Demonstrate Once-Daily Modified Release Prograf(R) Formula to Be Promising Treatment Option
- Multimedia News Release - RAZADYNE(TM) ER, New Once-Daily Treatment Option, Now Available for Patients With Mild to Moderate Alzheimer's Disease
- Comparative Efficacy of Once Daily, 5-Day Short-Course Therapy With Clarithromycin Extended-Release Versus Twice Daily, 7-Day Therapy With Clarithromycin Immediate-Release in Acute Bacterial Exacerbation of Chronic Bronchitis*
- Once Daily Clarithromycin Extended-Release Vs Twice-Daily Amoxicillin/Clavulanate in Patients With Acute Bacterial Sinusitis: a Randomized, Investigator-Blinded Study
 |
 |
User Comments (0)
RSS Feeds